Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jeffrey Zwicker MD

Jeffrey I. Zwicker MD

Chief of Benign Hematology, Beth Israel Deaconess Medical Center; Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts

Jeffrey Zwicker, MD, is an Associate Professor of Medicine at Harvard Medical School and Chief, Section of Benign Hematology, at Beth Israel Deaconess Medical Center. Dr. Zwicker has chaired a number of scientific committees including ISTH Subcommittee on Hemostasis and Cancer and ASH Subcommittee on Thrombosis and Vascular Biology. He is the co-organizer of the ASH workshop on the interplay of between coagulation and malignancy and associate editor for Journal of Thrombosis and Haemostasis. Dr. Zwicker leads an NIH-funded research program at Beth Israel Deaconess Medical Center with a focus on novel risk factors and therapeutic approaches to thrombotic disease with an emphasis on cancer-associated thrombosis.

Recent Contributions to PracticeUpdate:

  1. Association of Tumor-Expressed MicroRNAs With Venous Thromboembolism in Colorectal Cancer
  2. Biomarker Signatures in Cancer Patients With/Without VTE
  3. Thromboprophylaxis After Hospitalization for COVID-19
  4. ICH in Patients With Brain Metastases Receiving Anticoagulation
  5. Dynamic Assessment of Venous Thromboembolism Risk in Patients With Cancer by Longitudinal D-Dimer Analysis
  6. Safety of Primary Thromboprophylaxis Using Apixaban in Ambulatory Cancer Patients With Intracranial Metastatic Disease or Primary Brain Tumors
  7. A Clinical Prediction Model for Cancer-Associated VTE
  8. Comparison of an Oral Factor Xa Inhibitor With LMWH in Patients With Cancer With VTE

Recently Updated